Browse by Poster Presenter

Type here to filter the list

A
Abrams, Joshua

Critical Path Institute
(S-016) Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
Joshua Abrams
Favorite
Abulfathi, Ahmed

Certara USA Inc
(M-003) Characterizing the pharmacokinetics of MAM01, an extended half-life monoclonal antibody for the prevention of malaria using a population approach
Ahmed Abulfathi
Favorite
(M-004) Optimal Sampling Workflows with NMsim and NONMEM
Ahmed Abulfathi
Favorite
Aghaee, Mahya

University of Florida
(M-085) An innovative framework to find potential immunotherapy targets using QSP modeling and RNA-seq data
Mahya Aghaee
Favorite
Ahadieh, Sima

Pfizer
(S-046) Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
Sima Ahadieh
Favorite
Ahamadi, Malidi

Sanofi
(M-069) Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
Malidi Ahamadi
Favorite
Ahmadi Daryakenari, Nazanin

Biomedical Engineering, Brown University
(S-081) Leveraging Kolmogorov–Arnold Networks to Discover Time-Dependent Drug Efficacy Function
Nazanin Ahmadi Daryakenari
Favorite
Ahn, Jae Eun

Pfizer
(S-046) Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
Jae Eun Ahn
Favorite
Alaybeyoglu, Begum

Novartis
(S-106) Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction
Begum Alaybeyoglu
Favorite
Alexander, Gregory

Merck
(T-057) A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
Gregory Alexander
Favorite
Alidoost, Mohammadali

Pfizer
(M-078) Combining Mechanistic Modeling and Deep Learning for Predicting Survival Probabilities in Oncology
Mohammadali Alidoost
Favorite
Anbari Meybodi, Samira

Genmab US, Inc.
(S-094) Development of a Quantitative Systems Pharmacology (QSP) Model of the Complement System Capturing Crosstalk Between the Classical and Alternative Pathways
Samira Anbari Meybodi
Favorite
Anderson, Clifton

Simulations Plus
(M-014) Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study
Clifton Anderson
Favorite
(M-015) Hybrid MBMA-QSP Model Predicts T Cell Engager Plus Cereblon E3 Ligase Modulatory Drugs Combination Outcomes As A Function Of Prior Therapies In Relapsed/refractory Multiple Myeloma
Clifton Anderson
Favorite
Anderson, Hannah

Moffitt Cancer Center
(T-089) A Framework for Developing a Virtual Murine Cohort: Applications to Adoptive Cell Therapy in Bladder Cancer
Hannah Anderson
Favorite
Anderson, Wes

Critical Path Institute
(M-080) Harnessing Machine Learning and Real-World Data: Comparative Analysis of Cross-Sectional and Longitudinal Clustering in Patient Trajectories from Electronic Health Records
Wes Anderson
Favorite
Attarwala, Husain

Aera Therapeutics
(S-107) Semi-Mechanistic Model for LNP-mediated In-vivo CAR T-Cell Engineering and B-Cell Depletion in Primates
Husain Attarwala
Favorite
B
Bachina, Srinivas

Astrazeneca plc
(M-006) Risk Based Validation Strategy for Pharmacometric Analysis Ready Dataset to improve efficiency and effectiveness
Srinivas Bachina
Favorite
Balthasar, Martha

University of North Carolina at Chapel Hill
(T-050) A Mechanistic Pharmacokinetic-Pharmacodynamic Model Framework for Degrader-Antibody Conjugates
Martha Balthasar
Favorite
Bamgboye, Adeboye

University of Minnesota
(T-070) Development and External Validation of a Machine Learning Model to Predict Clearance in Patients with Epilepsy and Migraine Receiving Intravenous Topiramate with or without Enzyme-Inducing Comedications
Adeboye Bamgboye
Favorite
Barbarossa, Maria Vittoria

Abbvie
(S-056) Quantitative Assessment of Glecaprevir and Pibrentasvir Exposures in Adults with Chronic or Acute HCV Infection: A Comprehensive Analysis of Phase 2 and 3 Studies Utilizing Subject Matching and Population PK Simulations
Maria Vittoria Barbarossa
Favorite
Basu, Sanchita

Bristol Myers Squibb
(M-046) Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation
Sanchita Basu
Favorite
Bathena, Sai Praneeth

Bristol Myers Squibb
(M-008) Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
Sai Praneeth Bathena
Favorite
Battista, Christina

Simulations Plus
(T-096) Enabling Earlier Predictions of Hepatotoxic Risk with Quantitative Structure-Activity Relationship-Machine Learning (QSAR-ML) and Quantitative Systems Toxicology (QST) Models
Christina Battista
Favorite
Bazzazi, Hojjat

Moderna Inc
(M-079) Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model
Hojjat Bazzazi
Favorite
Bedathuru, Dinesh

Vantage Research Inc
(S-017) Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model
Dinesh Bedathuru
Favorite
(T-008) Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS
Dinesh Bedathuru
Favorite
Bender, Brendan

Genentech, Inc
(S-117) Predicting Clinical Mosunetuzumab CD20 Receptor Occupancy using a Minimal Physiologically–Based Pharmacokinetic (mPBPK) Modeling Approach
Brendan Bender
Favorite
Bhasi, Kavitha

C4 Therapeutics, Inc.
(M-095) Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Kavitha Bhasi
Favorite
Bishop, Corey

Johnson & Johnson
(T-103) A Fisher Information Matrix-based Analysis to Determine Precision of Estimated PK Parameters for Reduced Sample Sizes in Pediatric Studies in Rare Diseases
Corey Bishop
Favorite
Biswas, Sujit

Pfizer Inc.
(M-054) Population pharmacokinetics and exposure-safety analysis of SGN-STNV (PF-08046055) in patients with locally advanced and/or metastatic solid tumors: Phase-1a/b study
Sujit Biswas
Favorite
Boivin-Champeaux, Clémence

University of Florida
(S-062) Development of a Quantitative Systems Pharmacology Model for Hepatitis B Virus Infection and Hepatitis D Virus Co-Infection.
Clémence Boivin-Champeaux
Favorite
Boras, Britton
(T-066) QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations
Britton Boras
Favorite
Borek, Bartłomiej

Vertex Pharmaceuticals Inc
(M-032) Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
Bartłomiej Borek
Favorite
Bosley, James

Nova in silico
(M-019) In silico validation of MARIPOSA trial outcomes in EGFR‑mutated NSCLC using a QSP‑based disease model integrated with a newly implemented lazertinib drug model
James Bosley
Favorite
Bozenhardt, Emily

J&J Innovative Medicine
(S-071) Assessment of Virtual Control Groups for Organ Impairment Studies Using Population Pharmacokinetic Simulation: Twin Matching versus Group Matching
Emily Bozenhardt
Favorite
Braniff, Nathan

Pfizer
(T-071) Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Lorlatinib-treated Patients with Non-small Cell Lung Cancer
Nathan Braniff
Favorite
Brooks, Jordan

InsightRX
(M-050) Real-world Performance Assessment and Model Re-evaluation in Children and Adults
Jordan Brooks
Favorite
Burton, Jackson

Biogen
(M-111) Exposure-Response Relationship Between Litifilimab and Clinical Outcomes in Systemic Lupus Erythematosus Populations
Jackson Burton
Favorite
Buyukozturk, Fulden

Amgen
(T-028) A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Fulden Buyukozturk
Favorite
C
Cave, Joseph

Weill Cornell Medicine; Houston Methodist Research Institute
(S-093) Machine Learning-Integrated Physiology-Based Pharmacokinetic Modeling for Optimizing Nanoparticle Design
Joseph Cave
Favorite
Chacin Ruiz, Eduardo Andres

University at Buffalo, The State University of New York
(S-054) Computer Modeling of Bevacizumab Drug Distribution After Intravitreal Injection in Rabbit and Human Eyes
Eduardo Andres Chacin Ruiz
Favorite
Chakravarty, Arijit

Fractal Therapeutics
(S-009) A novel approach for predicting the efficacy of updated vaccines when the correlate of protection is known
Arijit Chakravarty
Favorite
(S-010) Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I
Arijit Chakravarty
Favorite
(S-116) A Novel Bayesian Adaptive Design for Phase I Dose Escalation with Improved Efficiency and Accuracy in Estimation of Maximum Tolerated Dose
Arijit Chakravarty
Favorite
Chamzas, Athanasios

University of Maryland School of Pharmacy
(T-104) Population Pharmacokinetics of Dexmedetomidine in Neonates with Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia: Insights from a Prospective Real-World Study
Athanasios Chamzas
Favorite
Chandra, Fiona

Amgen
(T-088) A Mechanistic Pharmacokinetic/Pharmacodynamic Model for CD19 Targeting Therapies for Autoimmune Diseases
Fiona Chandra
Favorite
Chang, Jason

Genentech/Johns Hopkins University
(T-091) gQSPTwin: A MATLAB-Based Application for Automation and Standardization of the QSP Digital Twin Generation Workflow
Jason Chang
Favorite
CHARBE, NITIN

Indiana University School of Medicine, Indianapolis, IN, USA
(T-105) Characterizing Chimeric Aducanumab Disposition in a Preclinical Alzheimer’s Model Using Population PK Modeling
NITIN CHARBE
Favorite
Chauvin, Jonathan

Simulations Plus
(S-072) Automated concentration-QT data preparation, model selection and reporting in R
Jonathan Chauvin
Favorite
Checchio, Tina

Pfizer
(M-016) Application of in silico Healthy Control Cohorts in the Analysis of Osivelotor Exposure in Organ Impairment
Tina Checchio
Favorite
Cheng, Limei

Incyte Corporation
(M-057) Quantitative Systems Pharmacology Modeling to Support First-in-Human Dose Selection for a CD3 Bispecific Antibody in B-Cell Lymphoma and Renal Cell Carcinoma
Limei Cheng
Favorite
(S-012) A Minimal-Quantitative Systems Pharmacology Model for Dual-Targeting Bispecific T Cell Modulators in Immuno-Oncology for Solid Tumors
Limei Cheng
Favorite
Cheng, Shen

College of Pharmacy, University of Minnesota
(M-065) Pharmacometrics and Machine Learning-Based Modeling to Assess the Impact of Vaginal Microbiome on Tenofovir Exposures in the Female Genital Tract of African Women
Shen Cheng
Favorite
Chen, Huili

Pfizer
(M-110) Re-evaluation of Fixed dosing versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults
Huili Chen
Favorite
Chen, Po-Wei

Amgen Inc.
(S-027) Implementation of Efron Correction for Tied-time Records in Time-variant and Time-invariant Cox Proportional Hazard Model in NONMEM
Po-Wei Chen
Favorite
Chen, Wenbo

Merck & Co., Inc.
(S-033) The Dose and Dosing Schedule Selection for an Investigational Immuno-Oncology Drug Based on a Pharmacokinetics and Pharmacodynamic Model of Tolerance
Wenbo Chen
Favorite
Chen, Xinyue

University of Florida
(S-038) A Physiologically Based Pharmacokinetic Model of Ceftriaxone in Healthy Adults and Pregnant Women
Xinyue Chen
Favorite
Chen, Yinbo

Bristol Myers Squibb
(M-013) QSP Model of Nivolumab in Combination with Bispecific T Cell Engagers predicts Enhanced Anti-Tumor Immunity
Yinbo Chen
Favorite
Cho, Yu Kyoung

Johnson and Johnson Innovative Medicine
(T-062) Exposure-Response Analysis of Guselkumab in the Maintenance Phase in Adults with Moderately to Severely Active Ulcerative Colitis
Yu Kyoung Cho
Favorite
Chung, Douglas

Certara Applied BioSimulation, Sheffield, United Kingdom
(M-059) Investigating the Role of Epithelial Barrier Function in Inflammatory Bowel Disease with Mechanistic Modeling
Douglas Chung
Favorite
Clark, Elias

Metrum Research Group
(M-104) Comparison of $PRED and $DES in NONMEM for time-varying categorical covariates in disease progression modeling.
Elias Clark
Favorite
Clary, James

Allucent, LLC
(M-029) Bayesian Analysis of Nonclinical Studies to Inform Regimen Selection for Tuberculosis
James Clary
Favorite
(T-022) Using Population Pharmacokinetics and Simulation to Develop SAT-3247 for the Treatment of Duchenne Muscular Dystrophy in Pediatric Patients
James Clary
Favorite
Cogny, Frederic

Nova In Silico
(M-025) Enhancing Model Interoperability and Workflow Integration in Clinical Trial Simulations
Frederic Cogny
Favorite
(M-026) Enhancing Clinical Trial Simulations with Advanced Computational Techniques and Scalable Cloud Solutions
Frederic Cogny
Favorite
(S-029) Supporting ICH M15 Principles Through a Collaborative Platform for Good Simulation Practices
Frederic Cogny
Favorite
(S-030) Automated Generation of Computational Models from Scientific Publications Using AI
Frederic Cogny
Favorite
(T-023) Optimizing Clinical Trial Design through In Silico Modeling, Virtual Populations, and Mathematical Optimization
Frederic Cogny
Favorite
(T-024) A Scalable, Traceable and Integrated Tool for Large QSP Models Calibration
Frederic Cogny
Favorite
Conchon Costa, Ana Carolina

University of Florida / Certara
(T-020) Comparison of Machine Learning and traditional Population Pharmacokinetic of Gabapentin in Neuropathic Pain
Ana Carolina Conchon Costa
Favorite
Cong, Shuangchen

Pfizer Pharmaceutical Ltd., Development China
(T-049) Monte-Carlo simulations to assess isavuconazole probability of pharmacokinetic-pharmacodynamic target attainment (PTA) for Chinese pediatric patients with invasive aspergillosis (IA) or invasive mucormycosis (IM)
Shuangchen Cong
Favorite
Contento, Lorenzo

Pumas-AI Inc.
(S-068) Machine learning for exploratory data analysis and model diagnosis in oncology
Lorenzo Contento
Favorite
Cruikshank, Allison

Duke University
(S-085) Investigating the Role of Estradiol in Oxidative Stress in Health and Disease: A Mechanistic Model
Allison Cruikshank
Favorite
Cui, Zihan

Critical Path Institute
(T-040) Disease progression model for TKV and eGFR prediction in patients with autosomal dominant polycystic kidney disease
Zihan Cui
Favorite
D
Dang, Xibei

PumasAI
(S-108) Impact of Misspecified Residual Error Model for Heavy-Tailed Error Distribution on PK Model Parameter Estimates
Xibei Dang
Favorite
Das, Sharmistha

Vertex Pharmaceuticals Incorporated
(T-027) Drug-drug interactions while breastfeeding with mother/infant medications: What's safe?
Sharmistha Das
Favorite
de Witte, Wilhelmus

ESQlabs GmbH
(T-004) Continuous infusion simulations in PBPK and QSP models reveal steady-state properties and rate-limiting steps.
Wilhelmus de Witte
Favorite
Desai, Devam

Center of Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL
(T-005) Bench to bedside modelling of mRNA encoding IgG using a multiscale mechanistic PK-PD model: A case study with anti-claudin 18.2
Devam Desai
Favorite
(T-006) Translational two-pore PBPK model to characterize whole-body disposition of different-size oligonucleotide therapeutics
Devam Desai
Favorite
Dhakal, Saroj

Sanofi
(T-106) DDIapp - A web-based application for static drug-drug interaction risk assessment.
Saroj Dhakal
Favorite
Dogra, Prashant

Houston Methodist Research Institute
(T-075) Mechanistic Modeling and Unsupervised Learning Reveal Drivers of Inter-Individual Variability in COVID-19 Vaccine-Induced Immunity
Prashant Dogra
Favorite
Dombrowsky, Erin

Bristol Myers Squibb
(S-007) Understanding the Utilization of SDTM and ADaM Datasets in Pharmacometric Programming
Erin Dombrowsky
Favorite
Dong, Min

Johnson & Johnson Innovative Medicine
(M-088) PK/PD Analysis of the Primary Endpoint for Nipocalimab in Sjögren's Disease
Min Dong
Favorite
Du, lihong

Merck & Co., Inc.,
(T-059) Characterizing the Exposure–Response Relationship of MK-2060 in Participants with End Stage Kidney Disease Receiving Hemodialysis
lihong Du
Favorite
Dumbleton, Jacob

A2-Ai, USA
(M-067) reportifyr: an R-based Open-Source Tool for Automated Reporting
Jacob Dumbleton
Favorite
Dunbar, Alexandra

University of Colorado Anschutz Medical Campus
(T-107) Use of Emtricitabine-Triphosphate Concentrations in Dried Blood Spots to Evaluate Pre-Exposure Prophylaxis (PrEP) Adherence
Alexandra Dunbar
Favorite
E
Elashkar, Omar

University of Florida
(S-070) Amplified Bioanalytical Uncertainty Propagation Impact on Population Pharmacokinetic Modeling
Omar Elashkar
Favorite
Elmokadem, Ahmed

Metrum Research Group
(M-051) Machine Learning Augmented Tumor Growth and Survival Models: Insights from Hepatocellular Carcinoma Data
Ahmed Elmokadem
Favorite
F
Fidler, Matthew

Novartis
(S-001) Easy model creation using nlmixr2shiny and nlmixr2lib
Matthew Fidler
Favorite
(S-002) nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2
Matthew Fidler
Favorite
Fischer-Holzhausen, Sophie

ESQlabs
(M-039) A Physiologically Based Pharmacokinetic Framework for Predicting Drug Exposure in the Female Reproductive Tract
Sophie Fischer-Holzhausen
Favorite
Franzese, Richard

GSK
(M-043) Model-based meta-analysis of objective response rate and overall survival in recurrent/metastatic head and neck squamous cell carcinoma
Richard Franzese
Favorite
Freshwater, Tomoko
(S-033) The Dose and Dosing Schedule Selection for an Investigational Immuno-Oncology Drug Based on a Pharmacokinetics and Pharmacodynamic Model of Tolerance
Tomoko Freshwater
Favorite
G
Gaitonde, Puneet

Pfizer Inc.
(S-043) Near Real-Time Apixaban Clinical Dose Decision-Making in Treating a Neonatal Venous Thromboembolism Population Using the InsightRX Nova™ Platform
Puneet Gaitonde
Favorite
Garhyan, Arnay

Park Tudor High School
(M-112) Development and Evaluation of PKPD Models for QT Interval Changes Post-Moxifloxacin Dosing in Non-Human Primates
Arnay Garhyan
Favorite
Gaurav, Mitali

Simulations Plus
(M-103) Population Pharmacokinetic Analysis of QRL-201 in Plasma and CSF in Patients With Amyotrophic Lateral Sclerosis From A First-in-Human Phase 1 Multiple Ascending Dose Escalation Study
Mitali Gaurav
Favorite
Ghusinga, Khem Raj

AstraZeneca
(S-067) Moment closure for uncertainty propagation in QSP models
Khem Raj Ghusinga
Favorite
Gibson, Elizabeth

Bristol Myers Squibb
(S-082) Model-Based Approach to Support Nivolumab Subcutaneous Dose Selection in Pediatric Patients (12 to <18 Years) in Multiple Solid Tumor Indications
Elizabeth Gibson
Favorite
GONG, CHANG

AstraZeneca
(S-087) A Quantitative Systems Pharmacology (QSP) Model Platform to Study the Impact of Intra-tumoral Heterogeneity on Antibody-Drug Conjugate (ADC) Treatment Efficacy
CHANG GONG
Favorite
Goo, Sungwoo

Institute of Drug Research & Development, Chungnam National University
(S-013) Proteosis-Targeting Chimera Efficacy Prediction Using a Deep-Learning–QSP Model
Sungwoo Goo
Favorite
(S-014) Survival Modeling of Dementia Risk Using Metabolic Syndrome-Related Genetic Variants
Sungwoo Goo
Favorite
Goryacheva, Ekaterina

InSysBio UK, Edinburgh, UK
(S-074) From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Ekaterina Goryacheva
Favorite
Gosselin, Nathalie

Certara
(T-080) Population Pharmacokinetic/Pharmacodynamic Modeling and Analysis of Tetrahydrobiopterin and Blood Phenylalanine Response in Adult and Pediatric Patients with Phenylketonuria During Sepiapterin Treatment
Nathalie Gosselin
Favorite
Goteti, Kosalaram

Seaport Therapeutics
(M-047) Prediction of human pharmacokinetic profiles of Glyph(TM) platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
Kosalaram Goteti
Favorite
Guan, Xiao-duo

Clinical Pharmacology, Development China, Pfizer Inc., Beijing, China
(S-055) Population Pharmacokinetics of Elranatamab in Chinese Patients with Relapsed or Refractory Multiple Myeloma using PRIOR Approach
Xiao-duo Guan
Favorite
Gunputh, Narshini

Rochester Institute of Technology
(M-063) Quantitative Model of the Ocular Immune Response to Seasonal Allergic Conjunctivitis
Narshini Gunputh
Favorite
Guo, Yizhen

Bristol Myers Squibb
(M-056) Time-to-event exposure-response based clinical utility index framework to facilitate optimal dose selection
Yizhen Guo
Favorite
GUPTA, PARIDHI

Bristol Myers Squibb
(M-007) Intravenous Immunoglobulin G (IVIG)-Monoclonal Antibody (mAb) Drug Interactions: Time for Model-Informed Clinical Guidance?
PARIDHI GUPTA
Favorite
(M-008) Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
PARIDHI GUPTA
Favorite
H
Hahn, Erik

Pfizer, Inc.
(S-105) POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Erik Hahn
Favorite
Haid, Robin

Bayer AG / Vividion Inc.
(M-058) Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection
Robin Haid
Favorite
Hai, Min

The Ohio State University
(S-102) Mathematical Modeling to Optimize Receptor Occupancy Assay Development for Isatuximab
Min Hai
Favorite
Hajjawi, Malek

Indiana University
(S-101) A Population Pharmacokinetic Approach to Prospectively Assess Vancomycin Pharmacokinetics in Adult Jordanian Patients: a Step towards Personalized Dosing
Malek Hajjawi
Favorite
Hallow, Melissa

Cardiorenal QSP, LLC
(T-052) Application of Neural ODEs for Agnostic Inference of Feedback Mechanism Structure in QSP Models
Melissa Hallow
Favorite
(T-053) QSP Modeling of Potassium Regulation in Rare and Complex Cardiorenal Disorders
Melissa Hallow
Favorite
Hamada, Izumi

Bristol Myers Squibb
(S-047) Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
Izumi Hamada
Favorite
Hayato, Seiichi

Eisai
(T-074) Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Patients with Solid Tumors
Seiichi Hayato
Favorite
Hegde, Renuka

Bristol Myers Squibb
(S-031) Case Study: Integrating ADPPK CDISC Standards into Pharmacometric Programming and Analysis Workflows
Renuka Hegde
Favorite
(S-032) Exploring Python to Prepare CDISC-Compliant Analysis Datasets for Pharmacometric Analyses
Renuka Hegde
Favorite
Henscheid, Nick

Critical Path Institute
(M-083) Disease progression simulation via generative AI: assessing the credibility of a conditional longitudinal autoencoder via a case study in Alzheimer’s Disease
Nick Henscheid
Favorite
Her, Lucy

Eli Lilly and Company
(T-010) Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
Lucy Her
Favorite
Herron, Cody

Pfizer
(T-066) QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations
Cody Herron
Favorite
Hosawi, Anhar

University of Cincinnati / Cincinnati Children's
(S-110) Simulating Relative Infant Hydroxyurea Dose Through Breastfeeding Using a Semi-Mechanistic Population PK Model
Anhar Hosawi
Favorite
Hsieh, Po-I

United Therapeutics Corporation
(T-097) Development of a Combined Deposition–Physiologically Based Pharmacokinetic Model for Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis
Po-I Hsieh
Favorite
Huang, Weize

Genentech
(T-047) Development of Dosing Selection Strategy for Brain Penetrants
Weize Huang
Favorite
Hu, Chuanpu

Bristol Myers Squibb
(S-042) Full covariate model construction, usage, and reduction in population pharmacokinetics
Chuanpu Hu
Favorite
Hughes, Jasmine

InsightRX
(T-068) Model selection for precision dosing: Comparison of Machine Learning and Evidence-plus-Expertise Algorithms
Jasmine Hughes
Favorite
Huisman, Marc

Amsterdam UMC, Amsterdam, The Netherlands
(T-045) 89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism
Marc Huisman
Favorite
Hunter, Asama

Teva Branded Pharmaceuticals LLC
(S-090) An Empirical Drug Autoinduction Model to Characterize the Population Pharmacokinetics of TEV-56286 (Emrusolmin) in Healthy Participants and Patients
Asama Hunter
Favorite
Hurh, Eunju
(M-095) Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Eunju Hurh
Favorite
Hu, Shihao

Janssen Research & Development
(S-006) Population Pharmacokinetics and Exposure-Response Analysis for TAR-200, an Intravesical Drug Delivery System for Bladder Cancer Treatment
Shihao Hu
Favorite
I
Iannuzzi, Sara

Freie Universität Berlin, Germany
(S-078) A Translational QSP Modeling Framework Demonstrates Tissue-Level Pharmacokinetics Do Not Predict the Clinical Efficacy of FTC/TDF PrEP
Sara Iannuzzi
Favorite
Iboi, Enahoro

Pfizer Inc.
(T-093) Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetic Variability of the PD-L1 Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Enahoro Iboi
Favorite
Ikari, Shinri

Kyowa Kirin Co., Ltd.
(T-025) Overcoming Temporal and Quality Challenges in Dataset Creation for Pharmacometrics Analysis
Shinri Ikari
Favorite
Illamola, Silvia M

Research Associate; Adjunct Assistant Professor
(S-113) Population pharmacokinetic analysis of sertraline in pregnant individuals
Silvia M Illamola
Favorite
Inoue, Shinsuke
(M-072) Population Pharmacokinetics and Pharmacodynamic Analysis of MT-4561, a Novel Bromodomain-containing Protein 4 (BRD4) Protein Degrader
Shinsuke Inoue
Favorite
Islam, Mohammad Aminul

University of Delaware
(M-077) Ocular Pharmacokinetic/Pharmacodynamic Modeling of Drug Release from Single- and Bi-Layered Polymeric Microspheres for Retinal Conditions
Mohammad Aminul Islam
Favorite
J
Javidi, Mehrdad

Janssen Research & Development, La Jolla, California, USA
(S-053) Leveraging historical clinical trial data using Model-Based Meta-Analysis (MBMA) to investigate the impact of prior biologic therapy on the efficacy of treatments in Psoriatic Arthritis
Mehrdad Javidi
Favorite
Jeong, Hyunjae

Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA
(M-041) Integrating Machine Learning and Magnetic Resonance Imaging Radiomics for Trajectory Modeling in Duchenne Muscular Dystrophy: Explainable Artificial Intelligence to Inform Clinical Trial Design and Personalized Intervention
Hyunjae Jeong
Favorite
Jeon, Hyeseon

Colleage of Pharmacy, Chungnam National University
(M-055) Real World Data Based Evaluation of a Novel TMDD Approximation Model
Hyeseon Jeon
Favorite
Jermain, Brian

Pfizer
(T-060) Clinical Utility Index Leveraging Results From Clinical Trial Simulation for Safety and Efficacy Outcomes Derived From Longitudinal Models
Brian Jermain
Favorite
Jin, Jin

Genentech, Inc.
(S-034) Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.
Jin Jin
Favorite
Job, Kathleen

The University of Utah
(T-095) Pharmacokinetic Modeling of Prophylactic Dose Rivaroxaban Transfer into Human Milk
Kathleen Job
Favorite
Johnson, Jordon

Arcus Biosciences Inc.
(S-096) Real-world Data Driven Pediatric Dose Extrapolation: A Novel Model-informed Drug Development Approach
Jordon Johnson
Favorite
Jones, Hannah

Certara
(S-052) Update on Current Status of PBPK Modeling Application in Hepatic Impairment Populations: Recent Successes & Knowledge Gaps
Hannah Jones
Favorite
Jonsson, E. Niclas

Pharmetheus AB
(T-069) Simplifying the Communication of Covariate Effects from Pharmacometric Models - The Role of Unconditional Covariate Effects
E. Niclas Jonsson
Favorite
Jung, Woojin

Senior Health Convergence Research Center, Chungnam National University
(S-044) Development of nmbench: A Lightweight NONMEM Workbench extension for Efficient Population Modeling and Simulation
Woojin Jung
Favorite
Jun, Heajin

Alnylam Pharmaceuticals
(M-086) Model-Based Evaluation of Lumasiran Plasma and Liver Pharmacokinetics in Non-Human Primates
Heajin Jun
Favorite
K
Kadry, Hossam

Pfizer Inc.
(S-084) Population pharmacokinetic modeling of anti-B7H4 antibody-drug conjugate (SGN-B7H4V) in patients with advanced solid tumors from phase 1 study
Hossam Kadry
Favorite
Kang, Dongwoo

Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, United States
(T-084) Population Pharmacokinetics of Deutetrabenazine in Asian Individuals
Dongwoo Kang
Favorite
Kang, Jia

Metrum Research Group, USA
(M-115) Dosage modifications in exposure-response analyses of oncology drug development: the brigimadlin case study
Jia Kang
Favorite
Karamitsou, Venetia

ESQlabs
(T-015) A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury
Venetia Karamitsou
Favorite
(T-016) Reducing Animal Use in Toxicological Research through Open-Source Individualized (PB)PK/QST Modeling: A Case Study with Phenobarbital in Dogs
Venetia Karamitsou
Favorite
Karas, Spinel

Pfizer Inc
(M-012) Population pharmacokinetics and pharmacodynamics analysis of PF-07328948, a branched-chain ketoacid dehydrogenase kinase inhibitor, in healthy participants
Spinel Karas
Favorite
Kawakatsu, Sonoko

Gilead Sciences, Inc.
(M-094) Population Pharmacokinetic Analysis of Zimberelimab in Patients with Solid Tumors
Sonoko Kawakatsu
Favorite
Kennard, Benjamin

Allucent
(S-059) Population Pharmacokinetic, Exposure-Response, and Time-To-Event Analyses of Probenecid in Symptomatic, Non-Hospitalized Patients with COVID-19
Benjamin Kennard
Favorite
Kim, Jaeyeon

Novartis
(S-045) Model-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization
Jaeyeon Kim
Favorite
Kim, Kyeongmin

The Ohio State University
(S-112) Sparse Sampling Strategies for Monoclonal Antibody Pharmacokinetics: Evaluating Estimation Methods for Reliable Clearance Assessment
Kyeongmin Kim
Favorite
Kim, Se Jin

University at Buffalo, SUNY
(T-086) PK/PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer
Se Jin Kim
Favorite
Knab, Timothy

Metrum Research Group
(S-095) A Julia Package for Traceable and Reproducible Models in Quantitative Systems Pharmacology
Timothy Knab
Favorite
Knöchel, Jane

InSilicoTrials Technologies S.p.A., Trieste, Italy.
(M-042) Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application
Jane Knöchel
Favorite
(M-044) A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Jane Knöchel
Favorite
Kosinski, Luke

Critical Path Institute
(T-058) Modeling Huntington’s disease progression utilizing the Huntington’s disease integrated staging system
Luke Kosinski
Favorite
Krzyzanski, Wojciech

University at Buffalo
(M-027) Implementation of Distributed Delay Differential Equations in RADAU5 and RADAR5
Wojciech Krzyzanski
Favorite
(T-014) ACS-SIMULATOR: A Shiny Application for Guiding Antenatal Corticosteroid Administration in Pregnant Women
Wojciech Krzyzanski
Favorite
Kulesza, Alexander

ESQlabs GmbH
(M-022) A multi-model strategy in R to address cytopenia
Alexander Kulesza
Favorite
(M-023) Towards uncertainty assessment-based acceptability thresholds for model validation?
Alexander Kulesza
Favorite
Kumbale, Carla

Pfizer
(T-064) Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity
Carla Kumbale
Favorite
Kuruvilla, Denison

Genentech
(T-046) Population Pharmacokinetics of Subcutaneous Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Denison Kuruvilla
Favorite
L
Lachi Silva, Larissa

Novartis
(S-089) Use of population time-activity curve modeling and simulation to support the reduced tumor dosimetry collection timepoints in radioligand therapy (RLT) clinical trials
Larissa Lachi Silva
Favorite
Langevin, Brooke

Center for Translational Medicine, University of Maryland Baltimore
(S-100) Understanding How Low Calorie Sweeteners Pass from Mother to Infants Through Breastmilk – Insights from Population Pharmacokinetic Modeling
Brooke Langevin
Favorite
Lee, Dongjin

Amgen
(S-023) Deep Learning-Based Autoencoder for Outlier Detection in Dosing and Concentration-Time Data: Enabling Reliable Population Pharmacokinetic Modeling
Dongjin Lee
Favorite
Lee, Grace

Critical Path Institute
(S-016) Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
Grace Lee
Favorite
Lennie, Janelle

GSK
(M-045) Ghqc: An R-based Open-Source Tool for Semi-Automated Quality Control on GitHub
Janelle Lennie
Favorite
Leonov, Vladislav

InSysBio UK Ltd
(M-068) Optimizing QSP Modeling Workflows with CYTOCON DB: A Comprehensive Repository of In Vivo Cell and Cytokine Concentrations
Vladislav Leonov
Favorite
(S-074) From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Vladislav Leonov
Favorite
Liang, Min

Moderna
(S-104) Model-Informed Dose Selection for mRNA-3927 in Participants with Propionic Acidemia (PA)
Min Liang
Favorite
Liao, Xiaozhi

UNC-Chapel Hill
(T-092) Mechanistic Modeling of Bispecific Antibody Combination Therapy to Optimize TumorKilling in Cancer Immunotherapy
Xiaozhi Liao
Favorite
Li, ChongHua
(T-094) Population Pharmacokinetics of Brensocatib in Adult and Adolescent Patients with Non-Cystic Fibrosis Bronchiectasis (BE)
ChongHua Li
Favorite
Lim, Jiwoo

College of Pharmacy, Yonsei University
(S-079) Osimertinib optimal dosing through population pharmacokinetics in virtual patients with NSCLC
Jiwoo Lim
Favorite
Lin, Chih-Wei

Amgen
(S-026) Evaluation of Fluctuating Drug Concentration and Pharmacokinetic Effects on Time-to-event Endpoint Using Proportional Hazard Cox Regression in NONMEM
Chih-Wei Lin
Favorite
Lindauer, Andreas

Calvagone SAS
(M-075) From hot to cold: Modeling radiocopper kinetics in Wilson’s Disease to simulate cold copper endpoints
Andreas Lindauer
Favorite
Lingineni, Karthik

Novartis Pharmaceutical Corporation
(M-106) An Integrated model of Lu-PSMA-617 dose, tumor dosimetry, PSA and OS to enable future study design
Karthik Lingineni
Favorite
Lin, Jiaye

Pfizer Ltd.
(T-002) Concentration-QTc modeling for ponsegromab using pooled data from 3 phase 1 studies in healthy participants
Jiaye Lin
Favorite
Linsmeier, Ian

Arcus Biosciences, Inc.
(T-044) GitHub-based QC Review Workflow for Pharmacometrics Projects
Ian Linsmeier
Favorite
Lint, Annabelle

University of Pittsburgh
(M-084) Modeling Blood Urea Nitrogen (urea) Dynamics to Estimate Dialysis Adequacy
Annabelle Lint
Favorite
Li, Peizhi

University of Iowa College of Pharmacy
(M-038) Evaluation of Azithromycin Disposition in Pregnant Women Undergoing Cesarean Delivery – A Population-Based PBPK Modeling Approach
Peizhi Li
Favorite
Liu, Catherine

UCSD
(M-009) Translation of a Preclinical Tumor Growth Inhibition Model to a Clinical Setting: Two Approaches to Incorporate Resistance in a Tumor Dynamics Model
Catherine Liu
Favorite
(M-010) Population Pharmacokinetic Modeling of Encorafenib and LHY746 In Participants with Solid Tumors in Phase 2 Studies: A Sequential Parent-Metabolite Model
Catherine Liu
Favorite
Liu, Xiaoxi

CSL Behring
(T-061) A semi-mechanistic PKPD model of CSL112 harmonizes the differential cholesterol efflux capacities (CEC) of high-density lipoprotein across different dose groups
Xiaoxi Liu
Favorite
Li, Xinnong

University at Buffalo
(T-019) Application of NSGA-II and pyDarwin in Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection
Xinnong Li
Favorite
Liyanage, Marlon

Pfizer Inc
(S-076) Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study
Marlon Liyanage
Favorite
Li, Yannuo
(M-057) Quantitative Systems Pharmacology Modeling to Support First-in-Human Dose Selection for a CD3 Bispecific Antibody in B-Cell Lymphoma and Renal Cell Carcinoma
Yannuo Li
Favorite
Li, Yingyi

Johnson and Johnson Innovative Medicine
(M-096) Simultaneous PASI Exposure Response Analysis of Ustekinumab in Subjects with Psoriasis and Psoriatic Arthritis
Yingyi Li
Favorite
Li, Yisheng

University of Texas MD Anderson Cancer Center
(T-041) An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information
Yisheng Li
Favorite
Li, zhenhong

Nimbus Therapeutics
(S-019) Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement
zhenhong Li
Favorite
Lohmer, Lauren

Indivior, Inc
(M-073) Exposure-Response Analyses for Monthly Buprenorphine Extended-Release (BUP-XR) in Patients with Opioid Use Disorder and Frequent Fentanyl Use
Lauren Lohmer
Favorite
Long, Yuhan

University of Minnesota
(M-097) Accounting for Temporal Differences in Fetal Exposure during Pregnancy using Masking
Yuhan Long
Favorite
Luanpaisanon, Alice

University of Virginia
(T-034) In silico model of hypertrophic cardiomyopathy caused by MYBPC3 mutation predicted key drivers of cardiomyocyte morphology
Alice Luanpaisanon
Favorite
Lu, Dan

Genentech
(M-092) QSP modeling to inform key clinical dosing regimen decisions for an engineered IL15 cytokine Efbalropendekin alfa in patients with solid tumors
Dan Lu
Favorite
Lumen, Annie

Clinical Pharmacology Modeling & Simulation, Amgen
(T-028) A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Annie Lumen
Favorite
Luo, Dandan

Johnson & Johnson
(M-020) Assessment of Drug-Drug Interaction Effect of Gastric Acid Reducing Agents on Lazertinib Exposure in EGFR-Mutated Non-Small Cell Lung Cancer
Dandan Luo
Favorite
M
Ma, Huilin

Bristol Myers Squibb
(S-049) Understanding PK/PD relationship of CD19 CAR-T (BMS-986353) in Systemic Lupus Erythematosus (SLE) using a mechanistic quantitative pharmacology framework
Huilin Ma
Favorite
Ma, Jessica
(T-078) Exposure-Response Modeling of Efficacy and Safety Endpoints of Sarilumab in Pediatric Patients with Polyarticular-Course Juvenile Arthritis
Jessica Ma
Favorite
Mapder, Tarunendu

Bristol Myers Squibb
(M-013) QSP Model of Nivolumab in Combination with Bispecific T Cell Engagers predicts Enhanced Anti-Tumor Immunity
Tarunendu Mapder
Favorite
Marcinowicz, Agnieszka

Premier Research
(M-102) Strategic application of PK modeling in 505(b)(2) development for a new pediatric formulation
Agnieszka Marcinowicz
Favorite
Masters, Joanna

Pfizer Inc
(M-071) Dose optimization framework to estimate benefit-risk for oncology compounds: an integrated population model framework incorporating PK, safety, efficacy and impact of dose modifications
Joanna Masters
Favorite
Mathew, Shibin

Pfizer Inc.
(M-062) Utilizing MechDermA model for early feasibility analysis in topical drug discovery
Shibin Mathew
Favorite
(T-054) Retrospective analysis of systemic and dermal PK of several anti-inflammatory topicals using SimCYP MechDermA model explains the observed clinical efficacy of successful and failed drugs
Shibin Mathew
Favorite
Mbuguiro, Wangui

AstraZeneca
(M-046) Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation
Wangui Mbuguiro
Favorite
McCune, Jeannine

Merck
(T-072) Population pharmacokinetic model-informed dose selection for exogenous hemopexin (CSL889) in patients with sickle cell disease
Jeannine McCune
Favorite
McDougall, Emily
(M-032) Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
Emily McDougall
Favorite
Meyer, Lyndsey

Pfizer
(S-092) Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies
Lyndsey Meyer
Favorite
Mitra, Amitava

Kura Oncology, Inc
(S-003) Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amitava Mitra
Favorite
(S-004) Exposure-Response Analysis of Ziftomenib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amitava Mitra
Favorite
Miyazawa, Kenji

Moderna, Inc.
(M-017) Comparative Sensitivity Analysis of Semi-mechanistic and QSP Models of Humoral Response Following Vaccination
Kenji Miyazawa
Favorite
(M-018) Construction of a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model to Facilitate the Design of LNP based mRNA Therapeutics for Secreted Protein Targets with Applications to Anti-Viral Therapies
Kenji Miyazawa
Favorite
(M-079) Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model
Kenji Miyazawa
Favorite
Mizuno, Morihiko

interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University
(S-080) Fluorescence timer-based analysis of latency-reversing agent effectiveness in HIV
Morihiko Mizuno
Favorite
Moore, Helen

University of Florida
(T-056) A novel mechanistic mathematical model of liver transplant immune dynamics predicts important drivers of patient outcome
Helen Moore
Favorite
Müller-Widmann, David

PumasAI
(M-099) Case Study: Parameter Estimation of an NLME-QSP Model
David Müller-Widmann
Favorite
Muthukrishnan, Venkateswari

CSL Behring
(T-085) Pharmacometric Modeling of Clazakizumab in Patients Undergoing Maintenance Dialysis
Venkateswari Muthukrishnan
Favorite
Myers, Renee

Rosa & Co. LLC
(T-012) Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations
Renee Myers
Favorite
N
Nagase, Mario

Bicycle Therapeutics
(M-082) A Novel Estimation Method for a Globally Unidentifiable Linear Compartment Models Using Bayesian Constraint Relaxation
Mario Nagase
Favorite
Nemoto, Takayuki

Chugai Pharmaceutical Co., Ltd.
(T-115) Quantitative investigation of ATP switch concept of STA551 by combined in vivo tissue distribution study and physiologically-based pharmacokinetic modeling
Takayuki Nemoto
Favorite
Nieves, Emily

Delineate Inc.
(M-060) Automated Model Generation with Delineate Co-Pilot
Emily Nieves
Favorite
O
Obianom, Obinna

Johnson and Johnson Innvoative Medicine
(S-077) Population Pharmacokinetic & Exposure-Response Analysis After Subcutaneous Administration of Guselkumab in Pediatric Participants with Moderate to Severe Plaque Psoriasis
Obinna Obianom
Favorite
Ogami, Chika

Chugai Pharmaceutical Co., Ltd.
(S-050) Quantitative systems modeling of inflammation and coagulation abnormalities induced by pathogen infection
Chika Ogami
Favorite
Osawa, Mayu

Bristol Myers Squibb
(M-049) Model Platform to Predict Overall Survival for Patients with Relapsed and Refractory Multiple Myeloma
Mayu Osawa
Favorite
P
Pallantla, Ravi Kumar
(S-018) Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model
Ravi Kumar Pallantla
Favorite
Papadopoulos, Stefanos

University of Pittsburgh
(M-035) Predicting Improved Weaning Strategies for Mechanical Ventilation with a Physiologically-Based Mechanistic Model
Stefanos Papadopoulos
Favorite
Park, Hyunseo

UTHSC, College of Pharmacy
(S-021) Development of a Physiologically Based Infection Kinetic Model to Assess Bacterial Clearance by Various Immunocompromised Mouse Strains Used as Infection Models for Mycobacterium abscessus
Hyunseo Park
Favorite
(S-022) Dose Optimization of Inhaled Tigecycline in Humans to Overcome Inherent Adverse Events and Maximize Bacterial Clearance Using a PBPK Modeling Approach
Hyunseo Park
Favorite
Park, Mina

Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA
(M-109) Optimizing Duchenne Muscular Dystrophy Clinical Trial Design by Modeling and Simulation: Identifying Characteristics of Magnetic Resonance Imaging Fat Fraction and Timed Function Test Measures and Their Longitudinal Association
Mina Park
Favorite
Park, Sung min

Allucent
(S-098) Population Pharmacokinetic Modeling of Rezpegaldesleukin after Subcutaneous Dosing to Account for Variability Across Multiple Patient Populations with Autoimmune Diseases
Sung min Park
Favorite
Parrot, Madison

University Of Utah
(S-088) A pediatric PBPK model of atropine gel to predict atropine levels in children with neurological disorders after administration to oral cavity
Madison Parrot
Favorite
Patel, Dimple

Kyowa Kirin Inc
(T-026) Semi-Automated Quality Check Process for NONMEM Dataset Using R Markdown
Dimple Patel
Favorite
Patel, Jayesh
(M-102) Strategic application of PK modeling in 505(b)(2) development for a new pediatric formulation
Jayesh Patel
Favorite
Penland, Chris
(M-005) Transforming Pharmacometric Processes to deliver medicines to patients: Balancing Speed, Quality, and Innovation
Chris Penland
Favorite
Pereira, Lucas

Pumas-AI
(S-068) Machine learning for exploratory data analysis and model diagnosis in oncology
Lucas Pereira
Favorite
Pham, Loan
(T-021) Utilizing Generative Deep Learning and Bayesian Neural Network for Pharmacometrics Covariate Analysis
Loan Pham
Favorite
Pillai, Nikhil

Sanofi
(S-039) Machine Learning and Mechanistic Modeling to Predict Intravenous Pharmacokinetic Profiles in Humans
Nikhil Pillai
Favorite
(T-038) From in vitro to in vivo via Machine Learning: Predicting preclinical pharmacokinetics for small molecules in the data-scarce regime
Nikhil Pillai
Favorite
Pinky, Lubna

Meharry Medical College
(M-081) Modeling Interactions Between Respiratory Pathogens
Lubna Pinky
Favorite
Pippa, Leandro

Certara USA, Inc. | University of Florida
(M-101) A minimal model to support a CAR T-cell therapy development platform
Leandro Pippa
Favorite
Poland, Bill

Certara
(T-033) Practical PK/PD Modeling of Lymphocytes and CD4+ T Cells in HIV Patients Treated with the Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) Islatravir
Bill Poland
Favorite
Poon, Victor

Genentech
(M-091) Auto-Induction and PD-Enhanced TMDD population PK Models for Engineered IL-15 cytokine Efbalropendekin alfa (XmAb24306) in Cancer Therapy
Victor Poon
Favorite
(M-092) QSP modeling to inform key clinical dosing regimen decisions for an engineered IL15 cytokine Efbalropendekin alfa in patients with solid tumors
Victor Poon
Favorite
Prabhakar, Vikram
(M-011) Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients
Vikram Prabhakar
Favorite
Pritchard-Bell, Ari

Amgen, Inc.
(S-025) A Novel Multi-Agent Framework for Automated Pharmacometric Analysis with Human-Like Reasoning
Ari Pritchard-Bell
Favorite
Pryor, Meghan

Johnson & Johnson
(M-034) Translating PROTACs: Relating in vitro Potency to Protein Degradation Kinetics
Meghan Pryor
Favorite
Psarellis, Yorgos

Sanofi US
(T-038) From in vitro to in vivo via Machine Learning: Predicting preclinical pharmacokinetics for small molecules in the data-scarce regime
Yorgos Psarellis
Favorite
Q
Qiu, Ruolun

Pfizer, Inc
(T-003) Simultaneous Modeling of Ponsegromab PK, PD and Clinical Response in Patients with Cancer Cachexia
Ruolun Qiu
Favorite
R
Ramakrishnan, Vidya

Genentech, Inc.
(S-034) Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.
Vidya Ramakrishnan
Favorite
Ramesh, Shyam

University of Florida
(T-043) Model-informed Clinical Trial Design for Autosomal Dominant Tubulointerstitial Kidney Disease: Integrating Disease Progression and Trial Simulation
Shyam Ramesh
Favorite
Randolph, Riley

University of North Carolina at Chapel Hill
(S-103) Model-Informed Oral Tacrolimus Dose Optimization for Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post-Transplant Cyclophosphamide
Riley Randolph
Favorite
Rao, Rohit

Pfizer
(T-090) Development and validation of a model-based framework to inform the preclinical to clinical translation of Mpro inhibitor antivirals
Rohit Rao
Favorite
Rattsev, Ilia

Johns Hopkins University
(M-098) Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling
Ilia Rattsev
Favorite
Ratushny, Alexander

Bristol Myers Squibb
(M-014) Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study
Alexander Ratushny
Favorite
Ravva, Patanjali

Pfizer Inc
(T-087) Exposure-Response Analysis of Bleeding Events Following Weekly SC Flat Dose Marstacimab Administration in Hemophilia Participants Using Regression Modeling and Repeated-Time-To-Event (RTTE) Analyses
Patanjali Ravva
Favorite
Reali, Federico

Fondazione COSBI
(S-051) First-In-Human TBD11 dose range prediction through a multispecies minimal PBPK model
Federico Reali
Favorite
Reddyhoff, Dennis

Certara
(T-051) Efficient Generation of Plausible Virtual Populations Using Machine Learning Surrogate Classification Models
Dennis Reddyhoff
Favorite
Reddy, Micaela

Pfizer
(T-055) Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application
Micaela Reddy
Favorite
Reilly, Brian

Clinical and Quantitative Pharmacology, Vertex Pharmaceuticals Inc.
(S-073) Automated simulation with parameter uncertainty from R with NONMEM and NMsim_NWPRI
Brian Reilly
Favorite
Rengaswamy, Maithreye

Vantage Research
(S-017) Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model
Maithreye Rengaswamy
Favorite
Reynaldo Fernandez, Gledys

University of Florida
(T-113) Model-informed Evidence Generation to Optimize Warfarin Dosing for Hepatic Impairment
Gledys Reynaldo Fernandez
Favorite
Rieger, Theodore

Pfizer Inc
(T-001) Optimization of Ponsegromab PK/PD Assessments in Phase 3 Studies by Clinical Trial Simulation
Theodore Rieger
Favorite
Rivera Rosario, Nicole

Arcus Biosciences
(S-058) Concentration-QTcF Analysis Indicates Casdatifan Does Not Prolong QTcF
Nicole Rivera Rosario
Favorite
Roberts, Jessica

Allucent, LLC
(S-091) Use of the Animal Rule to Develop JST-010 for Pre-Exposure Prophylaxis Against Infection by Yersinia pestis
Jessica Roberts
Favorite
Rodriguez Vera, Leyanis

Clinical Trial & Consulting (CTI)
(M-114) A Dose That Fits All: Model-Based Insights into the Impact of Obesity on Midazolam Oromucosal Pharmacokinetics in Adults
Leyanis Rodriguez Vera
Favorite
Roeshammar, Daniel

InsilicoTrials
(M-042) Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application
Daniel Roeshammar
Favorite
(M-044) A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Daniel Roeshammar
Favorite
Rojas, Luisa

Parexel International
(M-113) Characterization of PK Characteristics of IMMUNORHO after Intramuscular Administration for the Prevention of RhD Isoimmunisation in Rh(D) Negative Women Pregnant with Rh(D) Positive Fetuses: Population Pharmacokinetic Approach
Luisa Rojas
Favorite
Ruiz-Martinez, Alvaro

Rosa & Co. LLC
(T-011) Accurate modeling of ACTH and cortisol dynamics for Cushing’s disease treatment
Alvaro Ruiz-Martinez
Favorite
(T-012) Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations
Alvaro Ruiz-Martinez
Favorite
(T-013) Adaptable PBPK-QSP gene therapy model applied to i.v. administration of AAV-2 across different species
Alvaro Ruiz-Martinez
Favorite
Rupani, Dheeraj

AstraZeneca PLC
(M-005) Transforming Pharmacometric Processes to deliver medicines to patients: Balancing Speed, Quality, and Innovation
Dheeraj Rupani
Favorite
(M-006) Risk Based Validation Strategy for Pharmacometric Analysis Ready Dataset to improve efficiency and effectiveness
Dheeraj Rupani
Favorite
S
Salem, Ahmed

AsztraZeneca
(M-001) Prediction of Percent Free Nerve Growth Factor Suppression following Administration of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Osteoarthritis
Ahmed Salem
Favorite
(M-002) Population Pharmacokinetic Modeling of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Painful Osteoarthritis of the Knee
Ahmed Salem
Favorite
Sale, Mark

Certara
(T-018) Constrained Multi-Objective optimization population PK model selection in NLME and RDarwin.
Mark Sale
Favorite
Samiotakis, Antonios

AbCellera Biologics Inc.
(S-035) Mechanistic insights on diverse in vivo tumor efficacy outcomes for bispecific T-cell engagers using a quantitative systems pharmacology model
Antonios Samiotakis
Favorite
Samtani, Mahesh

Janssen R&D, USA
(S-077) Population Pharmacokinetic & Exposure-Response Analysis After Subcutaneous Administration of Guselkumab in Pediatric Participants with Moderate to Severe Plaque Psoriasis
Mahesh Samtani
Favorite
Sano, Yamato

Pfizer R&D Japan
(M-036) Mechanistic Insights by Combining Quantitative Systems Pharmacology (QSP) and Machine Learning: An Inflammatory Bowel Disease Case Study
Yamato Sano
Favorite
Santulli, Andrew

Enhanced Pharmacodynamics, LLC
(T-042) SimKid: An R package for Simulation of Virtual Pediatric Subjects
Andrew Santulli
Favorite
Schaller, Stephan

ESQlabs, GmbH
(T-114) Open-Source Modeling of Anti-Tuberculosis Drug-Induced Cardiac Risks for Safe Dose Prediction
Stephan Schaller
Favorite
Schneck, Karen

Eli Lilly and Company
(T-030) PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea
Karen Schneck
Favorite
Schulz Pauly, Julia

Amgen
(T-073) A PK/PD Model to Evaluate Uricosuric Clinical Efficacy versus Therapeutic Window for Treatment of Gout
Julia Schulz Pauly
Favorite
Seirin-Lee, Sungrim

Kyoto University
(T-116) Inference of Pathological States from Skin Eruption Morphology for Drug Efficacy Evaluation and Personalized Treatment in Skin Disease
Sungrim Seirin-Lee
Favorite
Shah, Millie

Biogen
(M-037) A quantitative systems pharmacology model of felzartamab, an anti-CD38 antibody, to link immune cell and pharmacodynamic responses in immune mediated diseases
Millie Shah
Favorite
Shahraz, Azar

AstraZeneca
(M-028) A Pharmacometrics Strategy for Ensuring Compatibility of Exposure-Response Analysis with Clinical Study Report: Enhancing Accuracy, Traceability, and Transferability Through Variable Mapping Specification (VMS)
Azar Shahraz
Favorite
Shah, Zeel

Bristol Myers Squibb
(T-029) A Model-Based Meta-Analysis Framework to Predict and Manage ADC-Related Grade 3+ Neutropenia Across Clinical Studies
Zeel Shah
Favorite
Shaik, Jafar Sadik

Johnson & Johnson Innovative Medicine
(T-083) Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program
Jafar Sadik Shaik
Favorite
Shannar, Ahmad

Rutgers - The State University of New Jersey
(T-037) Investigating tissue distribution of curcumin using Physiologically-based pharmacokinetic (PBPK) approach
Ahmad Shannar
Favorite
Shao, Shuai

Sanofi, Morristown, NJ USA
(M-069) Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
Shuai Shao
Favorite
(T-079) Population Pharmacokinetic Analysis to Characterize Pharmacokinetics of Sarilumab in Pediatric Participants with Polyarticular-Course Juvenile Idiopathic Arthritis
Shuai Shao
Favorite
Shapiro, Monica

Pfizer, Inc
(M-090) Pharmacoequivalence vs Bioequivalence: A role for MIDD analysis in bioequivalence studies
Monica Shapiro
Favorite
Sheng, Jennifer

Clinical Pharmacology and Pharmacometrics, Incyte
(S-111) Re-Purposing Bispecific Antibodies in Autoimmune Diseases: MIDD Based Dose Optimization Strategies
Jennifer Sheng
Favorite
Shenkoya, Babajide

University of Maryland School of Pharmacy, Baltimore, MD, USA
(T-109) A Multi-route, Multi-formulation Population Pharmacokinetic Framework for THC and 11-OH-THC Reflecting Real-World Use
Babajide Shenkoya
Favorite
Sherfey, Jason

Bristol Myers Squibb
(S-063) A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Jason Sherfey
Favorite
Sidi, Jonathan

Sanofi
(M-066) Model-informed Assessment of the Impact of Relaxing the high-sensitivity C-reactive protein Inclusion Criteria on Patient Enrollment and Efficacy Signal in Rheumatoid Arthritis Clinical Trial Design
Jonathan Sidi
Favorite
Siler, Scott

Simulations Plus
(M-100) Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics
Scott Siler
Favorite
Sinha, Jaydeep

Daiichi-Sankyo, Inc., USA
(T-100) Exposure-Response Analysis of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Patients with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Jaydeep Sinha
Favorite
Skataric, Maja

Merck
(T-032) Navigating Challenges in Dose-Exposure-Response Analysis in the Presence of Confounding Associated with Titrated Drug Regimens
Maja Skataric
Favorite
Smania, Giovanni

Pharmetheus AB
(S-075) Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia
Giovanni Smania
Favorite
Soliman, Amira

Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, USA
(T-036) Leveraging PBPK Modeling for Bioavailability Enhancement: Insights from In Vitro Dissolution and Cocrystallization Studies
Amira Soliman
Favorite
Song, Eric

Genmab
(T-039) Predicting Tumor Growth Dynamics and Overall Survival with Deep Learning Model
Eric Song
Favorite
Spinosa, Phillip

Genentech, Inc.
(T-007) Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs
Phillip Spinosa
Favorite
Srivastava, Ashish

University of Tennessee Health Science Center
(T-063) Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of a Novel, Directly Acting Antiviral, BDGR-251, in EEEV Infected Mice
Ashish Srivastava
Favorite
Stephens, Hunter

Certara
(M-108) Using Modeling and Simulation to Assess the Impact of the Pharmacokinetics and Biodistribution on the Absorbed and Biologically Effective Dose for Radioligand Therapies
Hunter Stephens
Favorite
Stodtmann, Sven

AbbVie
(M-024) A Population PK-PD Model-Informed Approach to Guide Formulation Development
Sven Stodtmann
Favorite
Subramanian, Kalyanasundaram

Differentia Biotech LTD
(S-061) Insights into Guide-Effector Antigen Interaction for Bispecific Antibody Design Using a Mechanistic Model
Kalyanasundaram Subramanian
Favorite
Sung, Kyeri

Sanofi
(M-076) Machine learning approach links QSP virtual populations with key lesion types and clinical scoring in hidradenitis suppurativa
Kyeri Sung
Favorite
Sun, Steven

UCSD
(S-105) POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Steven Sun
Favorite
Suriyapakorn, Bovornpat

University of Minnesota
(M-105) Designing Optimal Pharmacokinetic Sampling Strategies for Ketamine in Established Status Epilepticus: A Model-Based Simulation Study to Support the Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial
Bovornpat Suriyapakorn
Favorite
Susilo, Monica

Genentech
(T-091) gQSPTwin: A MATLAB-Based Application for Automation and Standardization of the QSP Digital Twin Generation Workflow
Monica Susilo
Favorite
Sutton, Karyn

Bristol Myers Squibb
(S-066) Right-Sizing Models: A Model Reduction Approach Applied to Models of the Treatment of Solid Tumors by Protein Degraders
Karyn Sutton
Favorite
T
Tagen, Michael

PumasAI
(S-114) A Bayesian Population Pharmacokinetic Analysis of Oritavancin in Pediatric Patients with Skin Infections
Michael Tagen
Favorite
Tang, Fei

Genentech
(M-053) Exploratory population pharmacokinetic analysis of vixarelimab using a two-target quasi-steady-state TMDD model in healthy volunteers and patients with pruritic conditions
Fei Tang
Favorite
Tang, Kayden

Central Bucks HS East
(T-092) Mechanistic Modeling of Bispecific Antibody Combination Therapy to Optimize TumorKilling in Cancer Immunotherapy
Kayden Tang
Favorite
Tang, Zoey

AstraZeneca
(S-048) Exposure-Response Analyses of Dato-DXd in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
Zoey Tang
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
(M-070) Population pharmacokinetic and exposure-response analysis of high-dose methotrexate-associated mucositis in infant patients with acute lymphoblastic leukemia
Zachary Taylor
Favorite
Thai, Hoai-Thu

Quantitative Pharmacology, Translational Medecine Unit, Sanofi
(T-099) Joint modeling of serum M-protein and PFS to predict response to isatuximab in combination with bortezomib/lenalidomide/dexamethasone in newly diagnosed multiple myeloma patients
Hoai-Thu Thai
Favorite
Thalluri, Bhargavi

The University if Tennessee Health Science Center
(T-081) A Population PK Approach to Evaluate Plasma and ELF Exposure Changes Following Co-administration of Spectinamide 1599 and Pyrazinamide in Mice
Bhargavi Thalluri
Favorite
Thiagarajan, Kannan

Vantage Research LLC
(M-011) Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients
Kannan Thiagarajan
Favorite
(S-018) Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model
Kannan Thiagarajan
Favorite
(T-009) Bridging Preclinical Data and Human Dose Selection for ADCs: Lessons from Approved Molecules
Kannan Thiagarajan
Favorite
Tirucherai, Giridhar

Scholar Rock, Inc.
(T-082) Population PK and PK/PD Modeling of Apitegromab in Spinal Muscular Atrophy Patients
Giridhar Tirucherai
Favorite
Tobin, Kevin

University of Maryland
(T-108) Right Dose, Wrong Patient? Clinical Perspectives on Atomoxetine Nonresponse in ADHD
Kevin Tobin
Favorite
Tong, Dominic

InsightRX
(T-112) Early sampling improves voriconazole target attainment in pediatric patients dosed with model-informed precision dosing tools: a simulation study
Dominic Tong
Favorite
Toukam, Marie

Biogen
(S-115) Population PK/PD Modeling to Optimize Dosing of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody
Marie Toukam
Favorite
Trogdon, Michael

Pfizer
(T-076) Virtual clinical trial simulations across treatment lines using a QSP model of CDK inhibitors in breast cancer patients
Michael Trogdon
Favorite
Tse, Andy

Bicycle Therapeutics
(M-089) Identifying an optimal dose range for clinical development of BT7480 using a fit-for-purpose quantitative system pharmacology (QSP) modeling
Andy Tse
Favorite
Tummala, Hari Prabhath

University of Michigan, Ann Arbor
(S-109) Mixed Effects Modeling of Diurnal Cortisol Dysregulation in Long COVID
Hari Prabhath Tummala
Favorite
Twarogowska, Monika

Simulations Plus
(S-057) mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM
Monika Twarogowska
Favorite
U
Usansky, Helen

Insmed Incorporated
(T-094) Population Pharmacokinetics of Brensocatib in Adult and Adolescent Patients with Non-Cystic Fibrosis Bronchiectasis (BE)
Helen Usansky
Favorite
V
Vo, Elise

Daiichi Sankyo, Inc.; Rutgers University
(T-035) Integrating Age-Related Immune Differences to Enhance Vaccine Response Predictions of a Quantitative Systems Pharmacology (QSP) Model
Elise Vo
Favorite
vo, Huy

BMS
(T-021) Utilizing Generative Deep Learning and Bayesian Neural Network for Pharmacometrics Covariate Analysis
Huy vo
Favorite
W
Wang, Kai

Amgen
(S-024) Population Pharmacokinetics of AMG 193 and its Impact on SDMA Inhibition in Patients with Advanced MTAP-deleted Solid Tumors
Kai Wang
Favorite
Wang, Mingyuan

critical path institute
(S-015) Improving Physical Activity Classification with Free-living Wrist Sensor Data: Diving into Unique Feature Groups
Mingyuan Wang
Favorite
(S-016) Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
Mingyuan Wang
Favorite
Wang, Xiaoning

Gilead Sciences, Inc.
(M-031) Exposure-Response Analysis of Seladelpar in Patients With Primary Biliary Cholangitis
Xiaoning Wang
Favorite
(S-020) Population Pharmacokinetic Analysis of Domvanalimab in Patients with Solid Tumors
Xiaoning Wang
Favorite
Wang, Yafei

Daiichi Sankyo Inc.
(S-086) QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Yafei Wang
Favorite
Wang, Yuchen

Pfizer
(S-041) A simulation-based Comparison of Approaches to Safety Outcome Estimation in Special Populations
Yuchen Wang
Favorite
Wang, Zixu

Bicycle Therapeutics
(T-031) Zelenectide Pevedotin, a Bicycle Drug Conjugate (BDC®), Does Not Present Clinically Meaningful QT Prolongation Risk as Demonstrated by A Concentration-QTc (C-QTc) Analysis
Zixu Wang
Favorite
Watanabe, Akiko

Daiichi Sankyo Co., Ltd.
(S-064) Physiologically Based Pharmacokinetic Modeling of Quizartinib to Assess Drug-Drug Interaction as an Inhibitor of Breast Cancer Resistance Protein
Akiko Watanabe
Favorite
Watkins, Lionel

University of Virginia
(M-064) Mechanistic Insights Uncover Novel Therapeutic Targets in Cardiac Hypertrophy
Lionel Watkins
Favorite
Wei, Zixuan

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
(T-077) Comparison of Population Pharmacokinetic Platforms, Monolix and Phoenix for Cephalexin in Infants
Zixuan Wei
Favorite
Wu, Wensi

University at Buffalo
(T-102) Methylprednisolone PK/PD in a Rat Model of Cytokine Release Syndrome
Wensi Wu
Favorite
X
Xu, Christine

Sanofi, Morristown, NJ, USA
(T-078) Exposure-Response Modeling of Efficacy and Safety Endpoints of Sarilumab in Pediatric Patients with Polyarticular-Course Juvenile Arthritis
Christine Xu
Favorite
Xu, Shuang

Certara, Inc.
(M-033) Population Pharmacokinetic Analysis of Possible Drug-Drug Interactions between Mouse Double Minute 2 (MDM2) Inhibitor Navtemadlin and the Bruton's Tyrosine Kinase (BTK) Inhibitor Acalabrutinib in Patients with R/R CLL or R/R DLBCL
Shuang Xu
Favorite
Y
Yamaguchi, Daichi

Shionogi & Co., Ltd.
(S-036) Modeling for prediction of CCR8 receptor occupancy in human tumor tissues after dosing of S-531011, a humanized anti-CCR8 monoclonal antibody
Daichi Yamaguchi
Favorite
Yamamoto, Shotaro

Nagoya University
(T-048) Modeling clinical trial design in infectious disease outbreaks considering differences in IC50 between in vitro and in vivo
Shotaro Yamamoto
Favorite
Yanamandala, Nitheesh

University at Buffalo
(T-110) PK/PD Modeling of Dexamethasone in Heart and Lung Tissues in an Animal Model of Cytokine Release Syndrome
Nitheesh Yanamandala
Favorite
Yan, Diqin

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN
(M-087) An Integrated PK-PD Model to Characterize Circadian-Driven ACTH-Cortisol Interactions in Patients with Congenital Adrenal Hyperplasia
Diqin Yan
Favorite
Yang, Tae Eun

Johnson & Johnson Innovative Medicine
(M-052) Exposure-Response Analysis of Guselkumab in Participants with Moderate to Severe Crohn’s Disease
Tae Eun Yang
Favorite
Yang, Xinxin

Bristol Myers Squibb
(S-065) Performance Verification and Application of Endogenous Biomarker Coproporphyrin I in the Simcyp™ Simulator V23
Xinxin Yang
Favorite
Yan, Xiaoyu

The Chinese University of Hong Kong
(S-040) Time-to-event analysis of iron homeostasis to inform survival in cancer patients
Xiaoyu Yan
Favorite
Yin, Xuefen

Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, USA
(S-069) Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Small-Molecule Oncology Drugs
Xuefen Yin
Favorite
Yuan, Dongfen

Johnson and Johnson
(S-005) Amivantamab population pharmacokinetics analyses of PALOMA studies supporting the bridging from intravenous formulation to subcutaneous formulation in epidermal growth factor receptor-mutated non-small cell lung cancer
Dongfen Yuan
Favorite
Yuan, Lin

Fractal Therapeutics
(S-009) A novel approach for predicting the efficacy of updated vaccines when the correlate of protection is known
Lin Yuan
Favorite
(S-010) Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I
Lin Yuan
Favorite
(S-011) Using translational in vitro-in vivo modeling to improve inhaled drug repurposing outcomes for COVID-19
Lin Yuan
Favorite
(S-116) A Novel Bayesian Adaptive Design for Phase I Dose Escalation with Improved Efficiency and Accuracy in Estimation of Maximum Tolerated Dose
Lin Yuan
Favorite
Yu, Yifan

University at Buffalo
(T-017) Multi-Objective Optimization for Population Pharmacokinetic Model Selection: Evaluating Non-dominated Sorting Genetic Algorithm III Performance
Yifan Yu
Favorite
Z
Zaidi, Syed Saoud

Indiana Univeristy
(T-111) Population Pharmacokinetics of Levocetirizine in Children with Uncontrolled Allergic Asthma: An Ongoing Study
Syed Saoud Zaidi
Favorite
Zaid, Nouran

Johns Hopkins
(T-067) Mathematical Modeling of Tumor Response to Fibroblast Activation Protein (FAP)-Targeted Radiopharmaceutical Therapy
Nouran Zaid
Favorite
Zhang, Mengxu

Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands
(S-037) Mechanism-based PBPK Modeling Reveals Nonlinear Brain Pharmacokinetics of Fluvoxamine: Roles of Active Influx and Brain Metabolism
Mengxu Zhang
Favorite
Zhang, Miao

Northeastern University
(T-101) Comparison of Predictive Performance of Complex IS/ID and Simple KPD Models on durability projections of Neutralizing Antibodies of LNP-mRNA-Based Vaccines
Miao Zhang
Favorite
Zhang, Xianwei

Boehringer Ingelheim
(S-083) PKPD investigation of BI-S across blood-ocular barrier
Xianwei Zhang
Favorite
Zhang, Yongzhen

St. Jude Children's Research Hospital
(M-107) Feasibility of predicting regional lung exposure from systemic pharmacokinetic data of generic orally inhaled drug products (OIDPs) via population pharmacokinetic and non-compartmental approaches
Yongzhen Zhang
Favorite
Zhang, Zhicheng

University of Florida
(M-040) Machine Learning and Chemical Language Model-Based QSAR Models for Predicting Plasma and Tissue Half-Lives of Drugs in Cattle Across Various Administration Routes
Zhicheng Zhang
Favorite
Zhao, Jinjin
(S-055) Population Pharmacokinetics of Elranatamab in Chinese Patients with Relapsed or Refractory Multiple Myeloma using PRIOR Approach
Jinjin Zhao
Favorite
Zheng, Fudan

Johnson & Johnson Innovative Medicine
(M-030) Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled Study
Fudan Zheng
Favorite
(S-008) Population PK-RO-IgG Modeling of Nipocalimab in Patients with Sjögren's Disease
Fudan Zheng
Favorite
Zmurchok, Cole

AbCellera
(S-035) Mechanistic insights on diverse in vivo tumor efficacy outcomes for bispecific T-cell engagers using a quantitative systems pharmacology model
Cole Zmurchok
Favorite